Spots Global Cancer Trial Database for Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
Official Title: A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
Study ID: NCT00697879
Conditions
Interventions
Study Description
Brief Summary: CHR-3996 is one of a new class of anti-cancer agents - histone deacetylase inhibitors (HDACi) - that has exhibited pleiotropic activity both in vitro and in vivo against a range of human cancer cells. Regulation of the acetylation of both histone and non-histone proteins by histone deacetylase enzymes is one of the key mechanisms involved in epigenetic control of gene expression. HDACi have demonstrated activity in both in vitro cytotoxicity, and in vivo tumour xenograft studies
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Erasmus MC University Medical Center - Location Centrum, Rotterdam, , Netherlands
Erasmus University Medical Center - Location Daniel den Hoed, Rotterdam, , Netherlands
The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Contact Details
Name: F ALM Eskens, Dr
Affiliation: Erasmus MC University Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: Udai Banerji, Dr
Affiliation: The Royal Marsden Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
